Bibliography
- PATEL NH, ROTHENBERG ML: Multidrug resistance in cancer chemotherapy. Invest. NewDrugs (1994) 12:1–13.
- AARONSON SA: Growth factors and cancer. Science (1991) 254:1146–1153.
- JACOBSON MD, WEIL M, RAFF MC: Programmed cell death in animal development. Cell (1997) 88:347–354.
- •Excellent apoptosis review.
- NAGATA S: Apoptosis by death factor. Cell (1997) 88:355–365.
- •Excellent apoptosis review.
- NAPOLI JL: Biochemical pathways of retinoid trans-port, metabolism, and signal transduction. Clin. Immu-nol. Immunopathol. (1996) 80:52–62.
- LOTAN R: Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J. Nail Cancer Inst. (1995) 87:1655–1657.
- ••Provides an excellent review of the problems related tothese therapeutic approaches.
- LI Y, DAWSON MI, AGADIR A et al: Regulation of RAR beta expression by RAR- and IVCR-selective retinoids in human lung cancer cell lines: Effect on growth inhibi-tion and apoptosis induction. Int. J. Cancer (1998) 75:88–95.
- HUANG C, MA WY, DAWSON MI et al.: Blocking activator protein-1 activity, but not activating retinoic acid re-sponse element, is required for the antitumor promo-tion effect of retinoic acid. Proc. Natl. Acad. Sci. USA (1997) 94:5826–5830.
- FANTL WJ, JOHNSON DE, WILLIAMS LT: Signalling by re-ceptor tyrosine kinases. Ann. Rev. Biochem. (1993) 62:453–481.
- LEVITZKI A, GAZIT A: Tyrosine kinase inhibition: an approach to drug development. Science (1995) 267:1782–1788.
- ••Provides an excellent review of the problems related tothese therapeutical approaches.
- TRAXLER PM: Protein tyrosine kinase inhibitors in can-cer treatment. Exp. Opin. Ther. Patents (1997) 7:571–588.
- WARRELL RP, DE-THE H., WANG ZY, DEGOS L: Acute promyelocytic leukemia. New Engl. J. Med. (1993) 329:177–189.
- KIZAKI M, UENO H, YAMAZOE Y et al.: Mechanisms ofretinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood (1996) 87:725–733.
- LU XP, FANJUL A, PICARD N et al: Novel retinoid-related molecules as apoptosis inducers and effective inhibi-tors of human lung cancer cells in vivo. Nature Med. (1997) 3:686–690.
- •Contains a lot of information about substances covered by one of the discussed patents.
- GRUNT TW, HUBER H: The family of c-erbB genes: from basic research to clinical oncology. Onkologie (1994) 17:346–357.
- JONESON T, BAR SD: Ras effectors and their role in mi-togenesis and oncogenesis. j Mol Med. (1997) 75:587–593.
- FERNANDES RS, MCGOWAN AJ, COTTER TG: Mutant H-ras overexpression inhibits drug and UV induced apoptosis. Anticancer Res. (1996) 16:1691–1705.